Galapagos receives €3.5 million in milestones in osteoarthritis alliance with Servier

Mechelen, Belgium; 02 March 2012 – Galapagos NV (Euronext: GLPG) and Servier announced today the achievement of milestones under their alliance agreement in osteoarthritis.  These milestones trigger payments to Galapagos totalling €3.5 million, which will contribute to the Company’s 2011 financial results.

In July 2010, Servier and Galapagos announced their alliance to develop new medicines for the treatment of osteoarthritis (OA).  Galapagos is responsible for the discovery and development of new candidate drugs, and Servier has an exclusive option to license these after the completion of Phase I clinical trials.  

“We are pleased that the molecules derived under the OA alliance have met the agreed criteria,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.  “This achievement brings us closer to delivering a pre-clinical candidate.”

“This is in line with Servier’s commitment to develop disease-modifying drugs for sufferers of uncured diseases, such as OA, a debilitating disease that affects 12% of the world population, leading to severe and costly handicaps,” said Bernard Marchand, Head of Discovery Research at Servier.

About Galapagos’ osteoarthritis alliance with Servier
The alliance between Servier and Galapagos builds on novel osteoarthritis drug targets discovered by Galapagos through its proprietary platform.  For any marketed products, Servier will have the rights to development, registration and commercialization, but Galapagos retains exclusive U.S. commercialization rights.  Galapagos is also eligible to receive discovery, development, regulatory and other milestone payments that could reach €290 million, plus royalties upon commercialization of products outside the U.S. covered under the agreement.

About osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis, typically affecting people aged 45 and older.  It is a degenerative disease characterized by joint destruction and loss of cartilage.  No currently available treatments prevent OA or even reverse or block the disease process.  Treatment of OA involves weight control, exercise, and pain relief, most frequently with non-steroidal anti-inflammatory drugs (NSAIDs) that relieve the symptoms without changing the course of the underlying disease.  Many OA patients have pain that persists despite these measures and often then have to undergo costly surgical procedures to replace their damaged joints.  It is expected that with the aging of the population, more individuals will be prone to develop OA.  As mobility of seniors is of high importance to maintaining a high quality of life, preventing the severity of OA is seen as an immense clinical need over the next decade.

About Servier
Servier is a privately-run research based pharmaceutical company with a 2011 turnover of €3.9 billion.  Servier is dedicating 25% of its turnover to Research & Development in cardiovascular, metabolic, neurological, psychiatric and bone and joint diseases as well as oncology.  Servier is established in 140 countries worldwide with over 20,000 employees.  More info at:

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 50 discovery programs.  The Galapagos Group has over 800 employees and operates facilities in six countries, with global headquarters in Mechelen, Belgium.  More info at:  


Servier                                                             Galapagos NV
Servier Communication Department                     Elizabeth Goodwin, Director Investor Relations
Tel:  +33 1 55 72 60 37                                      Tel: +31 6 2291 6240                                                

Cautionary note regarding forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,”  and “continues,” as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.